Video description compares NR and NMN NAD⁺ evidence and mixed trial results
The description cites a small crossover trial in which NR raised blood NAD more than NMN, a larger trial finding comparable NAD doubling, and meta-analyses and trials reporting little or no benefit on muscle, metabolic or long-COVID outcomes. [1]
Automatic summary · not editorially reviewed
The key findings
A Phase I crossover trial (n=6) found NR produced about 2.3 times higher blood NAD increase than NMN, with elevated NAAD linked to the Preiss-Handler pathway. [1]
A randomized controlled trial (n=65) found NR and NMN comparably doubled NAD at 14 days with no significant difference, and ex vivo gut data showed NR rapidly converted to nicotinic acid by bacteria. [1]
A meta-analysis of 10 trials in adults 60+ found no significant effect on muscle outcomes, and a long-COVID trial found tripled NAD but zero improvement in cognition, fatigue, sleep, anxiety or depression. [1]
The source at a glance
- Study type / format
- Video description summarizing cited trials and meta-analyses
- Population / context
- Adults in the cited trials and meta-analyses, including adults aged 60 and older and long-COVID patients.
- Summary based on
- Creator description
- Original publication
- April 3, 2026
Small crossover trial: NR versus NMN NAD rise
According to the description, a Phase I crossover trial (Berven 2026, n=6) found that NR produced about 2.3 times higher blood NAD increase than NMN. The same description says the trial also showed elevated NAAD, which it links to the Preiss-Handler pathway. This is a very small crossover comparison of blood NAD response, not an outcome study.
Supporting source [1]
Larger trial: comparable NAD doubling at 14 days
The description also cites Christen/Nature Metabolism 2025, a randomized controlled trial (n=65) in which NR and NMN comparably doubled NAD at 14 days, with no significant difference between them. It further reports ex vivo gut data showing NR rapidly converted to nicotinic acid by bacteria. These two cited studies therefore point in different directions on the NR-versus-NMN comparison.
Supporting source [1]
Meta-analyses and trials: little benefit on outcomes
The description lists a 2025 meta-analysis of 10 randomized controlled trials in adults aged 60 and older finding no significant effect on muscle mass, grip strength, gait speed or chair stand, concluding a negligible effect. A second meta-analysis (8 trials, 342 participants) reportedly found no significant improvement in fasting glucose, insulin, HbA1c or any lipid marker. A 2025 long-COVID trial of NR for 20 weeks reportedly tripled NAD levels but showed zero improvement in cognition, fatigue, sleep, anxiety or depression.
Supporting source [1]
How to interpret this
This is based only on the video description; the video and transcript were not reviewed. The description lists study details and citations but does not provide full methods, and the cited studies vary in size, design and outcomes.
Based on the creator’s description; the full video and transcript were not analyzed.
Source & supporting passages
Dr Brad Stanfield · youtube.com · April 3, 2026